arrow
I

Irene Bargellini

University of Turin
H指数:35
被引数:4,736

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Segmental versus subsegmental transarterial chemoembolization (TACE) for small (< 3 cm) hepatocellular carcinoma (HCC): Less selective, more effective? A propensity score-matched analysis

节段性 versus 亚段性经动脉化疗栓塞术(TACE)治疗小(<3 cm)肝细胞癌(HCC):选择性较低,效果更佳?一项倾向性评分匹配分析

2026-01-080
PRE
Bone Mineral Density Does Not Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial

骨矿物质密度不能预测晚期肝细胞癌患者的总生存期:SORAMIC试验的亚组分析

2026-01-010
PRE
Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

更正:EORTC和ESGAR关于局部和局部区域治疗中肝细胞癌分期、治疗计划制定和监测的影像学应用:共识建议

2025-10-310
OA
Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

在局部和局部区域治疗中,肝细胞癌分期、治疗计划和监测的影像学应用:EORTC和ESGAR的共识建议

2025-05-230
OA
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial
2024-07-153
OAAI
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients
2023-08-179
OA
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
2023-06-015
OAAI
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study

定义选择性内放射治疗肝细胞癌的教科书结果: 一项国际专家研究

2022-10-256
PRE
Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma
2022-08-290
OAAI
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
2022-08-023
OAAI
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
2022-05-180
OAAI